PriceTargets.com logo

Icon - ICLR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $205.00
  • Forecasted Upside: 10.35%
  • Number of Analysts: 20
  • Breakdown:
  • 0 Sell Ratings
  • 10 Hold Ratings
  • 8 Buy Ratings
  • 2 Strong Buy Ratings
$185.77 As of 12/4/2025 05:00 PM ET
▼ -2.01 (-1.07%)

This chart shows the closing price for ICLR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Icon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICLR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICLR

Analyst Price Target is $205.00
▲ +10.35% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for Icon in the last 3 months. The average price target is $205.00, with a high forecast of $263.00 and a low forecast of $150.00. The average price target represents a 10.35% upside from the last price of $185.77.

This chart shows the closing price for ICLR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 20 contributing investment analysts is to moderate buy stock in Icon. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 3 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/25/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/25/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
11/13/2025BMO Capital MarketsInitiated CoverageMarket Perform$175.00
10/27/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/24/2025CowenReiterated RatingHold ➝ Hold
10/24/2025UBS GroupSet Target$220.00
10/24/2025Robert W. BairdSet Target$220.00
10/24/2025TD CowenLower TargetHold ➝ Hold$183.00 ➝ $172.00
10/24/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$190.00 ➝ $185.00
10/23/2025Leerink PartnersSet Target$220.00
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/2/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$180.00 ➝ $190.00
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/12/2025CowenReiterated RatingHold ➝ Hold
9/9/2025Jefferies Financial GroupDowngradeBuy ➝ Hold$220.00 ➝ $175.00
9/3/2025Rothschild RedbUpgradeHold ➝ Strong-Buy
9/3/2025Rothschild & Co RedburnUpgradeNeutral ➝ Buy$184.00 ➝ $236.00
9/2/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$222.00 ➝ $224.00
8/21/2025CitigroupReiterated RatingBuy ➝ Neutral$225.00 ➝ $200.00
7/25/2025MizuhoBoost TargetOutperform ➝ Outperform$173.00 ➝ $225.00
7/25/2025Truist FinancialBoost TargetBuy ➝ Buy$187.00 ➝ $234.00
7/25/2025UBS GroupBoost TargetBuy ➝ Buy$170.00 ➝ $240.00
7/25/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$155.00 ➝ $180.00
7/25/2025Evercore ISIBoost TargetOutperform ➝ Outperform$170.00 ➝ $240.00
7/24/2025Baird R WUpgradeHold ➝ Strong-Buy
7/24/2025Robert W. BairdUpgradeNeutral ➝ Outperform$150.00 ➝ $224.00
7/9/2025Evercore ISIBoost TargetOutperform ➝ Outperform$155.00 ➝ $170.00
5/15/2025MizuhoLower TargetOutperform ➝ Outperform$200.00 ➝ $173.00
5/2/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$165.00 ➝ $155.00
5/2/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$180.00 ➝ $160.00
5/2/2025Robert W. BairdLower TargetNeutral ➝ Neutral$192.00 ➝ $160.00
4/29/2025JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$265.00 ➝ $150.00
4/14/2025TD CowenDowngradeBuy ➝ Hold$254.00 ➝ $157.00
4/10/2025BarclaysReiterated RatingOverweight ➝ Equal Weight$240.00 ➝ $165.00
4/10/2025Truist FinancialLower TargetBuy ➝ Buy$262.00 ➝ $208.00
4/9/2025MizuhoLower TargetOutperform ➝ Outperform$238.00 ➝ $200.00
4/7/2025CitigroupLower TargetBuy ➝ Buy$290.00 ➝ $215.00
3/21/2025The Goldman Sachs GroupDowngradeBuy ➝ Neutral$250.00 ➝ $200.00
3/4/2025Robert W. BairdLower TargetNeutral ➝ Neutral$221.00 ➝ $203.00
2/21/2025BarclaysLower TargetOverweight ➝ Overweight$275.00 ➝ $240.00
2/13/2025Truist FinancialLower TargetBuy ➝ Buy$284.00 ➝ $262.00
2/3/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$280.00 ➝ $265.00
1/15/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$263.00 ➝ $263.00
1/14/2025William BlairReiterated RatingOutperform ➝ Outperform
1/7/2025Royal Bank Of CanadaInitiated CoverageOutperform$263.00
1/6/2025CitigroupLower TargetBuy ➝ Buy$300.00 ➝ $290.00
12/18/2024Truist FinancialReiterated RatingBuy ➝ Buy$295.00 ➝ $284.00
11/20/2024Robert W. BairdLower TargetNeutral ➝ Neutral$249.00 ➝ $225.00
11/19/2024Leerink PartnersReiterated RatingOutperform ➝ Outperform$270.00 ➝ $255.00
10/28/2024Truist FinancialLower TargetBuy ➝ Buy$363.00 ➝ $295.00
10/25/2024TD CowenLower TargetBuy ➝ Buy$369.00 ➝ $285.00
10/25/2024BarclaysLower TargetOverweight ➝ Overweight$330.00 ➝ $275.00
10/25/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$375.00 ➝ $280.00
10/25/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$370.00 ➝ $280.00
10/25/2024Leerink PartnersLower TargetOutperform ➝ Outperform$376.00 ➝ $270.00
10/24/2024Baird R WDowngradeStrong-Buy ➝ Hold
10/24/2024Robert W. BairdDowngradeOutperform ➝ Neutral$340.00 ➝ $340.00
10/15/2024BarclaysLower TargetOverweight ➝ Overweight$350.00 ➝ $330.00
10/14/2024Truist FinancialLower TargetBuy ➝ Buy$383.00 ➝ $363.00
10/14/2024Redburn AtlanticInitiated CoverageNeutral$311.00
10/8/2024Evercore ISILower TargetOutperform ➝ Outperform$360.00 ➝ $350.00
9/20/2024Robert W. BairdLower TargetOutperform ➝ Outperform$368.00 ➝ $340.00
9/18/2024Leerink PartnrsUpgradeStrong-Buy
9/18/2024Leerink PartnersInitiated CoverageOutperform$379.00
9/11/2024Robert W. BairdReiterated RatingOutperform ➝ Outperform$368.00 ➝ $368.00
9/11/2024Truist FinancialReiterated RatingBuy ➝ Buy$383.00 ➝ $383.00
7/26/2024BarclaysLower TargetOverweight ➝ Overweight$355.00 ➝ $350.00
7/26/2024Truist FinancialBoost TargetBuy ➝ Buy$367.00 ➝ $383.00
7/8/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$367.00 ➝ $376.00
6/6/2024The Goldman Sachs GroupInitiated CoverageBuy$370.00
5/31/2024William BlairReiterated RatingOutperform
5/31/2024TD CowenBoost TargetBuy ➝ Buy$349.00 ➝ $373.00
5/31/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$363.00 ➝ $367.00
4/26/2024Evercore ISILower TargetOutperform ➝ Outperform$350.00 ➝ $330.00
4/26/2024TD CowenBoost TargetBuy ➝ Buy$343.00 ➝ $349.00
4/26/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$362.00 ➝ $363.00
4/4/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$345.00 ➝ $362.00
4/4/2024MizuhoReiterated RatingBuy ➝ Buy$346.00
2/23/2024MizuhoBoost TargetBuy ➝ Buy$315.00 ➝ $346.00
2/23/2024Evercore ISIBoost TargetOutperform ➝ Outperform$325.00 ➝ $350.00
2/23/2024BarclaysBoost TargetOverweight ➝ Overweight$325.00 ➝ $355.00
2/23/2024Truist FinancialBoost TargetBuy ➝ Buy$357.00 ➝ $367.00
1/25/2024BarclaysBoost TargetOverweight ➝ Overweight$280.00 ➝ $325.00
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$295.00 ➝ $330.00
12/15/2023Truist FinancialInitiated CoverageBuy$357.00
12/11/2023CitigroupBoost TargetBuy ➝ Buy$300.00 ➝ $315.00
10/17/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$278.00 ➝ $287.00
10/11/2023Evercore ISILower Target$290.00 ➝ $275.00
9/13/2023MizuhoReiterated RatingBuy ➝ Buy$274.00
9/13/2023TD CowenInitiated CoverageOutperform$306.00
7/28/2023BarclaysBoost TargetOverweight$250.00 ➝ $280.00
7/14/2023Deutsche Bank AktiengesellschaftBoost Target$280.00 ➝ $300.00
7/11/2023MizuhoBoost Target$250.00 ➝ $274.00
5/1/2023Robert W. BairdLower Target$280.00 ➝ $270.00
5/1/2023Wells Fargo & CompanyLower Target$245.00 ➝ $220.00
4/28/2023GuggenheimLower Target$271.00 ➝ $263.00
4/28/2023CitigroupLower Target$270.00 ➝ $250.00
4/4/2023BarclaysLower TargetOverweight$260.00 ➝ $250.00
2/24/2023Robert W. BairdBoost TargetOutperform$265.00 ➝ $285.00
1/20/2023GuggenheimBoost TargetBuy$255.00 ➝ $262.00
1/13/2023BarclaysUpgradeEqual Weight ➝ Overweight$215.00 ➝ $260.00
1/12/2023Robert W. BairdBoost TargetOutperform$260.00 ➝ $265.00
12/21/2022Robert W. BairdLower Target$265.00 ➝ $260.00
11/10/2022MizuhoLower TargetBuy$272.00 ➝ $250.00
11/9/2022Bank of AmericaUpgradeNeutral ➝ Buy$265.00 ➝ $260.00
10/18/2022Deutsche Bank AktiengesellschaftLower Target$295.00 ➝ $280.00
10/10/2022GuggenheimLower TargetBuy$278.00 ➝ $268.00
10/6/2022BarclaysLower TargetEqual Weight$240.00 ➝ $215.00
9/12/2022BarclaysLower TargetEqual Weight$260.00 ➝ $240.00
9/7/2022UBS GroupInitiated CoverageBuy$270.00
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$260.00
7/29/2022Deutsche Bank AktiengesellschaftBoost Target$285.00 ➝ $295.00
7/28/2022William BlairReiterated RatingOutperform
7/14/2022Deutsche Bank AktiengesellschaftLower TargetBuy$310.00 ➝ $285.00
7/13/2022BarclaysLower TargetEqual Weight$250.00 ➝ $245.00
7/8/2022CitigroupLower TargetBuy$315.00 ➝ $290.00
5/23/2022GuggenheimInitiated CoverageBuy$285.00
5/13/2022Robert W. BairdReiterated RatingBuy$285.00
4/25/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$280.00 ➝ $250.00
4/11/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$234.00 ➝ $310.00
3/7/2022MizuhoLower TargetBuy$315.00 ➝ $272.00
2/25/2022Deutsche Bank AktiengesellschaftLower TargetHold$287.00 ➝ $235.00
2/23/2022BarclaysLower TargetEqual Weight$285.00 ➝ $255.00
2/23/2022CitigroupLower TargetBuy$340.00 ➝ $315.00
1/27/2022BarclaysLower TargetEqual Weight$315.00 ➝ $285.00
11/16/2021Deutsche Bank AktiengesellschaftBoost TargetHold$234.00 ➝ $287.00
11/5/2021BarclaysBoost TargetEqual Weight$240.00 ➝ $315.00
11/5/2021MizuhoBoost TargetBuy$242.00 ➝ $315.00
9/27/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$230.00 ➝ $320.00
9/14/2021Jefferies Financial GroupBoost TargetBuy$276.00 ➝ $302.00
7/26/2021Deutsche Bank AktiengesellschaftBoost TargetHold$212.00 ➝ $234.00
7/23/2021CitigroupUpgradeNeutral ➝ Buy$260.00
7/23/2021Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$250.00 ➝ $280.00
7/23/2021Robert W. BairdBoost TargetOutperform$260.00 ➝ $265.00
7/20/2021Credit Suisse GroupBoost TargetOutperform$245.00 ➝ $250.00
7/14/2021CitigroupInitiated CoverageNeutral$220.00
5/3/2021MizuhoBoost TargetBuy$217.00 ➝ $242.00
4/29/2021Credit Suisse GroupBoost TargetOutperform$240.00 ➝ $245.00
4/29/2021Jefferies Financial GroupBoost TargetBuy$256.00 ➝ $267.00
4/13/2021Bank of AmericaInitiated CoverageNeutral
4/1/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$200.00 ➝ $235.00
3/8/2021BarclaysInitiated CoverageEqual Weight$200.00
3/8/2021Robert W. BairdUpgradeNeutral ➝ Outperform$215.00
3/2/2021BarclaysInitiated CoverageEqual Weight$200.00
3/1/2021UBS GroupUpgradeNeutral ➝ Buy$207.00 ➝ $232.00
2/26/2021Truist FinancialUpgradeHold ➝ Buy$280.00
2/25/2021Deutsche Bank AktiengesellschaftBoost TargetHold$179.00 ➝ $208.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.40 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 23 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
Mentions as of
5/8/2025
  • 1 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 14 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 5 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 13 very positive mentions
  • 13 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2025
  • 38 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 46 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 46 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Icon logo
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $185.77
Low: $174.13
High: $186.77

50 Day Range

MA: $175.90
Low: $156.49
High: $193.89

52 Week Range

Now: $185.77
Low: $125.10
High: $228.29

Volume

1,654,494 shs

Average Volume

905,686 shs

Market Capitalization

$15.00 billion

P/E Ratio

25.14

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Icon?

The following Wall Street research analysts have issued reports on Icon in the last year: Baird R W, Barclays PLC, BMO Capital Markets, Citigroup Inc., Cowen Inc, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Mizuho, Robert W. Baird, Rothschild & Co Redburn, Rothschild Redb, Royal Bank Of Canada, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for ICLR.

What is the current price target for Icon?

0 Wall Street analysts have set twelve-month price targets for Icon in the last year. Their average twelve-month price target is $205.00, suggesting a possible upside of 10.4%. Royal Bank Of Canada has the highest price target set, predicting ICLR will reach $263.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $150.00 for Icon in the next year.
View the latest price targets for ICLR.

What is the current consensus analyst rating for Icon?

Icon currently has 10 hold ratings, 8 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ICLR.

What other companies compete with Icon?

Other companies that are similar to Icon include Charles River Laboratories International, IQVIA, Thermo Fisher Scientific, Trip.com Group and Waste Connections. Learn More about companies similar to Icon.

How do I contact Icon's investor relations team?

Icon's physical mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company's listed phone number is (531) 291-2000. The official website for Icon is www.iconplc.com. Learn More about contacing Icon investor relations.